Navigation Links
Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
Date:3/17/2008

WOBURN, Massachusetts, March 17 /PRNewswire/ -- Mercury Therapeutics, Inc. (MTI), a company that discovers and develops orally active protein kinase targeted drugs, announces that it has retained Marquant Partners LLC (http://www.marquantpartners.com) to advise on its strategic and partnering opportunities, with the aim of maximizing value for MTI's shareholders.

This appointment follows a significant amount of interest that MTI has attracted from both financial and pharmaceutical companies after its announcement in November 2007 that it had made significant progress in its small molecule AMPK activator development program. Marquant is a specialist life sciences corporate finance boutique focused on advising privately held, small cap and emerging companies on licensing transactions, M&A, divestments, corporate strategy and company formation. Marquant's founders and principals are:

Dr. Pamela Joy Barton has over 12 years experience working with companies in the life sciences sector across the full spectrum of transactions - M&A, divestments, corporate partnering/licensing (inward and outward), IPOs and financings. Prior to Marquant, Joy's positions included: Vice President, Business Development at Nabi Biopharmaceuticals; Vice President, Business Development at Sosei Co. Ltd; Commercial Director at Xenova Group Limited; member of the Pharmaceuticals and Medical Products practice at Accenture; and various roles in the oncology therapeutic area with Novartis/Sandoz.

Dean Brown has over 14 years experience working as a transaction adviser to companies in the Life Sciences sector across the full spectrum of transactions - M&A, divestments, corporate partnering/licensing (inward and outward), and financings. Prior to Marquant, Dean spent almost 11 years as a partner with the Ferghana Partners Group, a boutique transaction advisory house operating in Europe and North America. During thi
'/>"/>

SOURCE Mercury Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
2. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
3. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
4. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
5. Nile Therapeutics, Inc. Adds to Executive Management Team
6. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
7. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
8. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
9. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
10. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
11. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013 Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... serious infectious diseases, announced today that Jeffrey Riley , ... New York Conference on Thursday, June 27, 2013 at The ... Mr. Riley is scheduled to present at 8:40 a.m. (Eastern ... can be accessed by logging onto the web at ...
(Date:6/19/2013)... , June 19, 2013 MO BIO ... and other challenging microbial nucleic acid purification, announces ... Kit, for extraction of pure protein from all ... coincides with the 20 th anniversary of ... capabilities. (Photo: http://photos.prnewswire.com/prnh/20130619/LA32633 ) ...
(Date:6/19/2013)... Calif. , June 19, 2013  Continuing its ... myocardial infarction (MI), Beckman Coulter , Inc. announces ... of its new Access AccuTnI+3 troponin I assay for ... "Clinicians have depended on Beckman Coulter,s ... new AccuTnI+3 assay has the proven performance to continue ...
(Date:6/19/2013)... --  NineSigma , Inc., of Cleveland ... NineSights.com is now the innovation engine for ... community of innovators. From technology developers, to ... stands out for its large community of innovators in ... all vetted by NineSigma. The community is free to ...
Breaking Biology Technology:Synthetic Biologics to Present at OneMedForum New York 2013 2MO BIO Laboratories, Inc. launches the first kit for protein extraction from soil 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3
... SOUTH PLAINFIELD, N.J., Aug. 10 PTC Therapeutics, Inc. ... its collaboration with Schering-Plough Corporation (NYSE: SGP ) receiving a ... for the treatment of hepatitis C virus (HCV) infection. , ... rnh/20010919/PTCLOGO ) , , The collaboration ...
... SHANGHAI, Aug. 10 /PRNewswire-Asia-FirstCall/ -- ... "the Company"), a leading Chinese firm,specializing in ... probiotics products, today announced that the Company,s,wholly-owned ... been,awarded the High-Technology Enterprise Certificate (the "Certificate") ...
... and VANCOUVER, Aug. 10 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... that the United States Patent and Trademark Office ... entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 ... cancer drug candidate, OGX-011, to treat certain cancers. ...
Cached Biology Technology:PTC Therapeutics Announces Achievement of Major Milestone in Schering-Plough Hepatitis C Collaboration 2PTC Therapeutics Announces Achievement of Major Milestone in Schering-Plough Hepatitis C Collaboration 3China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate 2China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate 3OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 2OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 3
(Date:6/19/2013)...  New York College of Health Professions announces the ... Trademark Office for detecting biometric changes through smart phones, ... been injured, attacked or killed. This patent ... Properties Agreements of New York College of Health Professions. ... New York College says, "Our Chairman, ...
(Date:6/19/2013)... ITHACA, N.Y. A Cornell University study offers further ... 4 million to 6 million years ago was profoundly ... in turning genes on and off. , The study, ... evidence for a 40-year-old hypothesis that regulation of genes ... is little difference between humans and chimps in the ...
(Date:6/19/2013)... Midwest are expected to contribute to a very large ... according to a University of Michigan ecologist and colleagues ... for the Chesapeake Bay. , The Gulf forecast, one ... Administration, calls for an oxygen-depleted, or hypoxic, region of ... it among the 10 largest on record. , The ...
Breaking Biology News(10 mins):New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4New research backs theory that genetic 'switches' play big role in human evolution 2New research backs theory that genetic 'switches' play big role in human evolution 3U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 2U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 3U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 4
... by the International Osteoporosis Foundation (IOF) show alarming projections ... the Russian Federation and many other countries in the ... conference in St. Petersburg at the IOF Summit of ... Osteoporosis, a disease of the bone which leaves people ...
... Santa Cruz, CA, USA and Oxford, UK, 27 September ... shows a new method of enzyme-controlled movement of ... The paper, by researchers at the University of ... nanopore sequencing of DNA strands. The publication describes the ...
... Carolina State University researcher has shown that water-gel-based solar ... cells to produce electricity. The findings prove the concept ... They also have the potential to be less expensive ... solar cells. The bendable devices are composed of ...
Cached Biology News:High death and disability rates due to fractures in Russia, Central Asia and Eastern Europe 2Nature Nanotechnology paper shows enzyme-controlled movement of DNA polymer through a nanopore 2Mimicking nature, water-based 'artificial leaf' produces electricity 2
... Ideal for hand-held applications or for use ... with a hand-held eight-port disposable manifold provides ... a multi-channel pipette. The StatMatic II can ... sizes and can completely fill a microplate ...
...
... tube gel adaptors, 24 glass tubes ... grommets, stoppers. The PROTEAN II xi cell ... the versatility to perform a variety of ... electrophoresis, native, preparative, and gradient PAGE as ...
StemSep Anti-Phycoertherin Tetrameric Antibody Complexes, 2 mL for labeling 1x10 9 cells. Cross-linking Reagent for StemSep Separations of Cells Labeled with PE-conjugated Antibody....
Biology Products: